硫唑嘌呤治疗炎症性肠病发生淋巴瘤的风险研究进展(5)
[27]Sánchez Rodríguez E，Ríos León R，Mesonero Gismero F，et al.Clinical experience of optimising thiopurine use through metabolite measurement in inflammatory bowel disease[J].Gastroenterol Hepatol，2018，41(10)：629-635.
[28]Hanauer SB，Sandborn WJ，Lichtenstein GR.Evolving considerations for thiopurine therapy for inflammatory bowel diseases-a clinical practice update：commentary[J].Gastroenterology，2019，156(1)：36-42.
[29]Magro F，Gionchetti P，Eliakim R，et al.Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis.Part 1：Definitions，diagnosis，extra-intestinal manifestations，pregnancy，cancer surveillance，surgery，and ileo-anal pouch disorders[J].J Crohns Colitis，2017，11(6)：649-670.
[30]Barnes EL，Herfarth HH.The usefulness of serologic testing for Epstein-Barr virus before initiation of therapy for inflammatory bowel disease[J].Gastroenterology，2017，153(4)：1167.
[31]Honkila M，Niinim■ki R，Taskinen MM，et al.A nearly fatal primary Epstein-Barr virus infection associated with low NK-cell counts in a patient receiving azathioprine：a case report and review of literature[J].BMC Infect Dis，2019，19(1)：404.
[32]Rahier JF，Magro F，Abreu C，et al.Second European evidence-based consensus on the prevention，diagnosis and management of opportunistic infections in inflammatory bowel disease[J].J Crohns Colitis，2014，8(6)：443-468.
[33]Feng R，Guo J，Zhang SH，et al.Low 6-thioguanine nucleotide level：Effective in maintaining remission in Chinese patients with Crohn′s disease[J].J Gastroenterol Hepatol，2019，34(4)：679-685.
[34]Estevinho MM，Afonso J，Rosa I，et al.A systematic review and Meta-analysis of 6-thioguanine nucleotide levels and clinical remission in inflammatory bowel disease[J].J Crohns Colitis，2017，11(11)：1381-1392.
(收稿日期：2019-08-14 本文編辑：任秀兰), 百拇医药(申艳丽 张安兴 罗娟)
[28]Hanauer SB，Sandborn WJ，Lichtenstein GR.Evolving considerations for thiopurine therapy for inflammatory bowel diseases-a clinical practice update：commentary[J].Gastroenterology，2019，156(1)：36-42.
[29]Magro F，Gionchetti P，Eliakim R，et al.Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis.Part 1：Definitions，diagnosis，extra-intestinal manifestations，pregnancy，cancer surveillance，surgery，and ileo-anal pouch disorders[J].J Crohns Colitis，2017，11(6)：649-670.
[30]Barnes EL，Herfarth HH.The usefulness of serologic testing for Epstein-Barr virus before initiation of therapy for inflammatory bowel disease[J].Gastroenterology，2017，153(4)：1167.
[31]Honkila M，Niinim■ki R，Taskinen MM，et al.A nearly fatal primary Epstein-Barr virus infection associated with low NK-cell counts in a patient receiving azathioprine：a case report and review of literature[J].BMC Infect Dis，2019，19(1)：404.
[32]Rahier JF，Magro F，Abreu C，et al.Second European evidence-based consensus on the prevention，diagnosis and management of opportunistic infections in inflammatory bowel disease[J].J Crohns Colitis，2014，8(6)：443-468.
[33]Feng R，Guo J，Zhang SH，et al.Low 6-thioguanine nucleotide level：Effective in maintaining remission in Chinese patients with Crohn′s disease[J].J Gastroenterol Hepatol，2019，34(4)：679-685.
[34]Estevinho MM，Afonso J，Rosa I，et al.A systematic review and Meta-analysis of 6-thioguanine nucleotide levels and clinical remission in inflammatory bowel disease[J].J Crohns Colitis，2017，11(11)：1381-1392.
(收稿日期：2019-08-14 本文編辑：任秀兰), 百拇医药(申艳丽 张安兴 罗娟)